Literature DB >> 21720059

Kinetics of serum β-D-glucan after Pneumocystis pneumonia treatment in patients with AIDS.

Michiko Koga1, Tomohiko Koibuchi, Tadashi Kikuchi, Hitomi Nakamura, Toshiyuki Miura, Aikichi Iwamoto, Takeshi Fujii.   

Abstract

OBJECTIVE: Serum β-D-glucan has been demonstrated as a reliable, adjunct diagnostic marker for PCP, but its kinetics after PCP treatment are poorly understood. To evaluate the correlation between the levels of β-D-glucan and the clinical response, we investigated the individual transition of serum β-D-glucan levels after the initiation of PCP treatment.
METHODS: Retrospective study PATIENTS: Seventeen PCP patients with AIDS who were admitted to our hospital were analyzed.
RESULTS: All subjects showed the serum β-D-glucan levels above the cut-off value, and the median level was 224 pg/mL [IQR: 78-597] at the time of PCP diagnosis. There were no correlations between serum β-D-glucan levels and CRP, LDH, or AaDO(2) at room air. Although there was a downward trend in serum β-D-glucan level as PCP treatment was initiated, a significant number of subjects showed a marked increase in the serum β-D-glucan levels despite their evident clinical improvement.
CONCLUSION: The serum β-D-glucan level does not reflect the severity and prognosis of PCP infection, and thus it may not be suitable for monitoring the response to treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21720059     DOI: 10.2169/internalmedicine.50.5296

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  5 in total

1.  Post-diagnostic kinetics of the (1 → 3)-β-D-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia.

Authors:  S Koo; L R Baden; F M Marty
Journal:  Clin Microbiol Infect       Date:  2012-03-08       Impact factor: 8.067

2.  Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China.

Authors:  Yan-Hui Chen; Xue-Yao Fang; Yue-Ting Li; Yan-Ling Liu; Ya-Ping Hang; Yan-Ping Xiao; Xing-Wei Cao; Qiao-Shi Zhong; Long-Hua Hu
Journal:  Braz J Microbiol       Date:  2020-05-03       Impact factor: 2.476

3.  Serum Aspergillus galactomannan for the management of disseminated histoplasmosis in AIDS.

Authors:  Sébastien Rivière; Blandine Denis; Marie-Elisabeth Bougnoux; Fanny Lanternier; Marc Lecuit; Olivier Lortholary
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

4.  Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis.

Authors:  Dionysios Neofytos; Radha Railkar; Kathleen M Mullane; David N Fredricks; Bruno Granwehr; Kieren A Marr; Nikolaos G Almyroudis; Dimitrios P Kontoyiannis; Johan Maertens; Rebecca Fox; Cameron Douglas; Robert Iannone; Eunkyung Kauh; Norah Shire
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

Review 5.  Pneumocystis Pneumonia in Human Immunodeficiency Virus-infected Adults and Adolescents: Current Concepts and Future Directions.

Authors:  Sadatomo Tasaka
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.